Is NXTC or GOSS more profitable?

NextCure has a net margin of 0.00% compared to Gossamer Bio's net margin of -324.82%. Gossamer Bio's return on equity of 0.00% beat NextCure's return on equity. Company Net Margins Return on Equity Return on Assets NextCure N/A -186.96% -124.62% Gossamer Bio -324.82% N/A -96.10%

Does the media favor NXTC or GOSS?

In the previous week, Gossamer Bio had 17 more articles in the media than NextCure. MarketBeat recorded 21 mentions for Gossamer Bio and 4 mentions for NextCure. Gossamer Bio's average media sentiment score of 0.10 beat NextCure's score of 0.04 indicating that Gossamer Bio is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment NextCure 0 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 1 Very Negative mention(s) Neutral Gossamer Bio 2 Very Positive mention(s) 1 Positive mention(s) 15 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Which has higher earnings and valuation, NXTC or ESLA?

Estrella Immunopharma is trading at a lower price-to-earnings ratio than NextCure, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio NextCure N/A N/A -$55.84M -$17.19 N/A Estrella Immunopharma N/A N/A -$13.06M -$0.34 N/A

Is NXTC or ESLA more profitable?

Estrella Immunopharma's return on equity of 0.00% beat NextCure's return on equity. Company Net Margins Return on Equity Return on Assets NextCure N/A -186.96% -124.62% Estrella Immunopharma N/A N/A -397.36%

Does the media favor NXTC or ESLA?

In the previous week, NextCure had 3 more articles in the media than Estrella Immunopharma. MarketBeat recorded 4 mentions for NextCure and 1 mentions for Estrella Immunopharma. Estrella Immunopharma's average media sentiment score of 0.87 beat NextCure's score of 0.04 indicating that Estrella Immunopharma is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment NextCure 0 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 1 Very Negative mention(s) Neutral Estrella Immunopharma 0 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Positive

Do analysts rate NBRV or NXTC?

NextCure has a consensus target price of $23.00, suggesting a potential upside of 591.73%. Given NextCure's stronger consensus rating and higher possible upside, analysts plainly believe NextCure is more favorable than Nabriva Therapeutics. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Nabriva Therapeutics 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 NextCure 2 Sell rating(s) 0 Hold rating(s) 3 Buy rating(s) 0 Strong Buy rating(s) 2.20

Which has preferable earnings & valuation, NXTC or ACTU?

Actuate Therapeutics is trading at a lower price-to-earnings ratio than NextCure, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio NextCure N/A N/A -$55.84M -$17.19 N/A Actuate Therapeutics N/A N/A -$22.23M -$0.97 N/A

Is NXTC or ACTU more profitable?

NextCure's return on equity of -186.96% beat Actuate Therapeutics' return on equity. Company Net Margins Return on Equity Return on Assets NextCure N/A -186.96% -124.62% Actuate Therapeutics N/A -430.93% -180.86%

Does the media favor NXTC or ACTU?

In the previous week, NextCure had 2 more articles in the media than Actuate Therapeutics. MarketBeat recorded 4 mentions for NextCure and 2 mentions for Actuate Therapeutics. Actuate Therapeutics' average media sentiment score of 1.29 beat NextCure's score of 0.04 indicating that Actuate Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment NextCure 0 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 1 Very Negative mention(s) Neutral Actuate Therapeutics 1 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Which has stronger valuation & earnings, ELUT or NXTC?

Elutia has higher revenue and earnings than NextCure. NextCure is trading at a lower price-to-earnings ratio than Elutia, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Elutia $12.29M 3.64 $53.38M $0.86 1.22 NextCure N/A N/A -$55.84M -$17.19 N/A

Is ELUT or NXTC more profitable?

Elutia has a net margin of 312.09% compared to NextCure's net margin of 0.00%. Elutia's return on equity of 0.00% beat NextCure's return on equity. Company Net Margins Return on Equity Return on Assets Elutia 312.09% N/A -53.97% NextCure N/A -186.96% -124.62%

NextCure (NXTC) Competitors

$3.32 +0.18 (+5.56%)

As of 01:57 PM Eastern

Compare

NXTC vs. GOSS, ESLA, NBRV, ACTU, and ELUT

Should you buy NextCure stock or one of its competitors? MarketBeat compares NextCure with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with NextCure include Gossamer Bio (GOSS), Estrella Immunopharma (ESLA), Nabriva Therapeutics (NBRV), Actuate Therapeutics (ACTU), and Elutia (ELUT). These companies are all part of the "pharmaceutical products" industry.

How does NextCure compare to Gossamer Bio?

NextCure (NASDAQ:NXTC) and Gossamer Bio (NASDAQ:GOSS) are both small-cap medical companies, but which is the better stock? We will compare the two companies based on the strength of their valuation, dividends, media sentiment, analyst recommendations, institutional ownership, earnings, risk and profitability.

42.7% of NextCure shares are owned by institutional investors. Comparatively, 81.2% of Gossamer Bio shares are owned by institutional investors. 11.9% of NextCure shares are owned by insiders. Comparatively, 7.2% of Gossamer Bio shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

NextCure presently has a consensus price target of $23.00, suggesting a potential upside of 591.73%. Gossamer Bio has a consensus price target of $5.00, suggesting a potential upside of 2,647.25%. Given Gossamer Bio's higher possible upside, analysts clearly believe Gossamer Bio is more favorable than NextCure.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
NextCure	2 Sell rating(s)	0 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.20
Gossamer Bio	2 Sell rating(s)	4 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.20

In the previous week, Gossamer Bio had 17 more articles in the media than NextCure. MarketBeat recorded 21 mentions for Gossamer Bio and 4 mentions for NextCure. Gossamer Bio's average media sentiment score of 0.10 beat NextCure's score of 0.04 indicating that Gossamer Bio is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
NextCure	0 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	1 Very Negative mention(s)	Neutral
Gossamer Bio	2 Very Positive mention(s)	1 Positive mention(s)	15 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

NextCure has a beta of 1.3, suggesting that its share price is 30% more volatile than the broader market. Comparatively, Gossamer Bio has a beta of 2, suggesting that its share price is 100% more volatile than the broader market.

NextCure has a net margin of 0.00% compared to Gossamer Bio's net margin of -324.82%. Gossamer Bio's return on equity of 0.00% beat NextCure's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
NextCure	N/A	-186.96%	-124.62%
Gossamer Bio	-324.82%	N/A	-96.10%

NextCure has higher earnings, but lower revenue than Gossamer Bio. Gossamer Bio is trading at a lower price-to-earnings ratio than NextCure, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
NextCure	N/A	N/A	-$55.84M	-$17.19	N/A
Gossamer Bio	$48.47M	0.88	-$170.37M	-$0.79	N/A

Summary

Gossamer Bio beats NextCure on 10 of the 14 factors compared between the two stocks.

How does NextCure compare to Estrella Immunopharma?

NextCure (NASDAQ:NXTC) and Estrella Immunopharma (NASDAQ:ESLA) are both small-cap medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their media sentiment, analyst recommendations, institutional ownership, dividends, earnings, risk, valuation and profitability.

Estrella Immunopharma is trading at a lower price-to-earnings ratio than NextCure, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
NextCure	N/A	N/A	-$55.84M	-$17.19	N/A
Estrella Immunopharma	N/A	N/A	-$13.06M	-$0.34	N/A

In the previous week, NextCure had 3 more articles in the media than Estrella Immunopharma. MarketBeat recorded 4 mentions for NextCure and 1 mentions for Estrella Immunopharma. Estrella Immunopharma's average media sentiment score of 0.87 beat NextCure's score of 0.04 indicating that Estrella Immunopharma is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
NextCure	0 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	1 Very Negative mention(s)	Neutral
Estrella Immunopharma	0 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Positive

42.7% of NextCure shares are owned by institutional investors. Comparatively, 0.4% of Estrella Immunopharma shares are owned by institutional investors. 11.9% of NextCure shares are owned by insiders. Comparatively, 5.8% of Estrella Immunopharma shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

Estrella Immunopharma's return on equity of 0.00% beat NextCure's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
NextCure	N/A	-186.96%	-124.62%
Estrella Immunopharma	N/A	N/A	-397.36%

NextCure presently has a consensus price target of $23.00, suggesting a potential upside of 591.73%. Estrella Immunopharma has a consensus price target of $8.00, suggesting a potential upside of 598.69%. Given Estrella Immunopharma's higher probable upside, analysts plainly believe Estrella Immunopharma is more favorable than NextCure.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
NextCure	2 Sell rating(s)	0 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.20
Estrella Immunopharma	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

NextCure has a beta of 1.3, suggesting that its stock price is 30% more volatile than the broader market. Comparatively, Estrella Immunopharma has a beta of 0.85, suggesting that its stock price is 15% less volatile than the broader market.

Summary

NextCure beats Estrella Immunopharma on 8 of the 13 factors compared between the two stocks.

How does NextCure compare to Nabriva Therapeutics?

Nabriva Therapeutics (NASDAQ:NBRV) and NextCure (NASDAQ:NXTC) are both small-cap medical companies, but which is the superior stock? We will compare the two businesses based on the strength of their valuation, institutional ownership, analyst recommendations, profitability, dividends, risk, media sentiment and earnings.

NextCure has a net margin of 0.00% compared to Nabriva Therapeutics' net margin of -148.11%. NextCure's return on equity of -186.96% beat Nabriva Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Nabriva Therapeutics	-148.11%	-365.53%	-135.81%
NextCure	N/A	-186.96%	-124.62%

0.3% of Nabriva Therapeutics shares are held by institutional investors. Comparatively, 42.7% of NextCure shares are held by institutional investors. 1.6% of Nabriva Therapeutics shares are held by insiders. Comparatively, 11.9% of NextCure shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

NextCure has lower revenue, but higher earnings than Nabriva Therapeutics. NextCure is trading at a lower price-to-earnings ratio than Nabriva Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Nabriva Therapeutics	$35.59M	0.00	-$57.19M	-$19.20	N/A
NextCure	N/A	N/A	-$55.84M	-$17.19	N/A

In the previous week, NextCure had 4 more articles in the media than Nabriva Therapeutics. MarketBeat recorded 4 mentions for NextCure and 0 mentions for Nabriva Therapeutics. NextCure's average media sentiment score of 0.04 beat Nabriva Therapeutics' score of 0.00 indicating that NextCure is being referred to more favorably in the news media.

Company	Overall Sentiment
Nabriva Therapeutics	Neutral
NextCure	Neutral

NextCure has a consensus target price of $23.00, suggesting a potential upside of 591.73%. Given NextCure's stronger consensus rating and higher possible upside, analysts plainly believe NextCure is more favorable than Nabriva Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Nabriva Therapeutics	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00
NextCure	2 Sell rating(s)	0 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.20

Nabriva Therapeutics has a beta of 1.53, suggesting that its stock price is 53% more volatile than the broader market. Comparatively, NextCure has a beta of 1.3, suggesting that its stock price is 30% more volatile than the broader market.

Summary

NextCure beats Nabriva Therapeutics on 12 of the 15 factors compared between the two stocks.

How does NextCure compare to Actuate Therapeutics?

NextCure (NASDAQ:NXTC) and Actuate Therapeutics (NASDAQ:ACTU) are both small-cap medical companies, but which is the superior business? We will contrast the two companies based on the strength of their risk, media sentiment, dividends, profitability, analyst recommendations, valuation, institutional ownership and earnings.

Actuate Therapeutics is trading at a lower price-to-earnings ratio than NextCure, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
NextCure	N/A	N/A	-$55.84M	-$17.19	N/A
Actuate Therapeutics	N/A	N/A	-$22.23M	-$0.97	N/A

42.7% of NextCure shares are owned by institutional investors. 11.9% of NextCure shares are owned by insiders. Comparatively, 58.0% of Actuate Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.

NextCure's return on equity of -186.96% beat Actuate Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
NextCure	N/A	-186.96%	-124.62%
Actuate Therapeutics	N/A	-430.93%	-180.86%

NextCure presently has a consensus price target of $23.00, indicating a potential upside of 591.73%. Actuate Therapeutics has a consensus price target of $17.50, indicating a potential upside of 818.64%. Given Actuate Therapeutics' stronger consensus rating and higher probable upside, analysts plainly believe Actuate Therapeutics is more favorable than NextCure.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
NextCure	2 Sell rating(s)	0 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.20
Actuate Therapeutics	1 Sell rating(s)	0 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.33

NextCure has a beta of 1.3, meaning that its stock price is 30% more volatile than the broader market. Comparatively, Actuate Therapeutics has a beta of 0.52, meaning that its stock price is 48% less volatile than the broader market.

In the previous week, NextCure had 2 more articles in the media than Actuate Therapeutics. MarketBeat recorded 4 mentions for NextCure and 2 mentions for Actuate Therapeutics. Actuate Therapeutics' average media sentiment score of 1.29 beat NextCure's score of 0.04 indicating that Actuate Therapeutics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
NextCure	0 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	1 Very Negative mention(s)	Neutral
Actuate Therapeutics	1 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Summary

NextCure beats Actuate Therapeutics on 7 of the 13 factors compared between the two stocks.

How does NextCure compare to Elutia?

Elutia (NASDAQ:ELUT) and NextCure (NASDAQ:NXTC) are both small-cap medical companies, but which is the superior investment? We will compare the two companies based on the strength of their dividends, earnings, profitability, analyst recommendations, risk, media sentiment, institutional ownership and valuation.

In the previous week, NextCure had 4 more articles in the media than Elutia. MarketBeat recorded 4 mentions for NextCure and 0 mentions for Elutia. Elutia's average media sentiment score of 1.87 beat NextCure's score of 0.04 indicating that Elutia is being referred to more favorably in the media.

Company	Overall Sentiment
Elutia	Very Positive
NextCure	Neutral

Elutia has higher revenue and earnings than NextCure. NextCure is trading at a lower price-to-earnings ratio than Elutia, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Elutia	$12.29M	3.64	$53.38M	$0.86	1.22
NextCure	N/A	N/A	-$55.84M	-$17.19	N/A

74.0% of Elutia shares are held by institutional investors. Comparatively, 42.7% of NextCure shares are held by institutional investors. 27.6% of Elutia shares are held by insiders. Comparatively, 11.9% of NextCure shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

Elutia presently has a consensus target price of $6.00, indicating a potential upside of 474.16%. NextCure has a consensus target price of $23.00, indicating a potential upside of 591.73%. Given NextCure's higher possible upside, analysts plainly believe NextCure is more favorable than Elutia.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Elutia	0 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.50
NextCure	2 Sell rating(s)	0 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.20

Elutia has a beta of 0.8, indicating that its share price is 20% less volatile than the broader market. Comparatively, NextCure has a beta of 1.3, indicating that its share price is 30% more volatile than the broader market.

Elutia has a net margin of 312.09% compared to NextCure's net margin of 0.00%. Elutia's return on equity of 0.00% beat NextCure's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Elutia	312.09%	N/A	-53.97%
NextCure	N/A	-186.96%	-124.62%

Summary

Elutia beats NextCure on 11 of the 15 factors compared between the two stocks.

Get NextCure News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding NXTC and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

NXTC vs. The Competition

Export

Metric	NextCure	MED Industry	Medical Sector	NASDAQ Exchange
Market Cap	$12.00M	$3.34B	$6.43B	$12.45B
Dividend Yield	N/A	2.37%	2.69%	5.22%
P/E Ratio	-0.19	18.80	23.85	24.37
Price / Sales	N/A	320.09	522.03	117.40
Price / Cash	N/A	110.40	41.27	57.13
Price / Book	0.33	6.83	10.04	6.75
Net Income	-$55.84M	$24.09M	$3.56B	$337.03M
7 Day Performance	-48.05%	-2.36%	-0.82%	0.08%
1 Month Performance	N/A	N/A	N/A	-1.66%
1 Year Performance	-41.43%	48.79%	28.88%	34.01%

NextCure Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
NXTC NextCure	3.4709 of 5 stars	$3.33 +5.6%	$23.00 +591.7%	-44.6%	$12.00M	N/A	N/A	90	News Coverage
GOSS Gossamer Bio	2.0361 of 5 stars	$0.20 +1.1%	$5.00 +2,397.5%	-84.6%	$46.99M	$55.54M	N/A	180	Analyst Revision
ESLA Estrella Immunopharma	2.7273 of 5 stars	$1.08 -3.6%	$8.00 +640.7%	+27.7%	$46.48M	N/A	N/A	N/A	News Coverage Short Interest Decrease
NBRV Nabriva Therapeutics	N/A	N/A	N/A	N/A	$45.46M	$35.59M	N/A	70
ACTU Actuate Therapeutics	3.0911 of 5 stars	$1.88 -5.5%	$17.50 +830.9%	-81.3%	$44.98M	N/A	N/A	10	Gap Up

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:NXTC) was last updated on 6/4/2026 by MarketBeat.com Staff.

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

NextCure (NXTC) Competitors

NXTC vs. GOSS, ESLA, NBRV, ACTU, and ELUT

How does NextCure compare to Gossamer Bio?

Summary

How does NextCure compare to Estrella Immunopharma?

Summary

How does NextCure compare to Nabriva Therapeutics?

Summary

How does NextCure compare to Actuate Therapeutics?

Summary

How does NextCure compare to Elutia?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

NXTC vs. The Competition

NextCure Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

NextCure (NXTC) Competitors

NXTC vs. GOSS, ESLA, NBRV, ACTU, and ELUT

How does NextCure compare to Gossamer Bio?

Do institutionals and insiders have more ownership in NXTC or GOSS?

Do analysts prefer NXTC or GOSS?

Does the media favor NXTC or GOSS?

Which has more risk & volatility, NXTC or GOSS?

Is NXTC or GOSS more profitable?

Which has stronger earnings & valuation, NXTC or GOSS?

Summary

How does NextCure compare to Estrella Immunopharma?

Which has higher earnings and valuation, NXTC or ESLA?

Does the media favor NXTC or ESLA?

Do insiders & institutionals have more ownership in NXTC or ESLA?

Is NXTC or ESLA more profitable?

Do analysts prefer NXTC or ESLA?

Which has more volatility and risk, NXTC or ESLA?

Summary

How does NextCure compare to Nabriva Therapeutics?

Is NBRV or NXTC more profitable?

Do institutionals and insiders hold more shares of NBRV or NXTC?

Which has stronger earnings and valuation, NBRV or NXTC?

Does the media refer more to NBRV or NXTC?

Do analysts rate NBRV or NXTC?

Which has more risk and volatility, NBRV or NXTC?

Summary

How does NextCure compare to Actuate Therapeutics?

Which has preferable earnings & valuation, NXTC or ACTU?

Do insiders and institutionals believe in NXTC or ACTU?

Is NXTC or ACTU more profitable?

Do analysts recommend NXTC or ACTU?

Which has more volatility and risk, NXTC or ACTU?

Does the media favor NXTC or ACTU?

Summary

How does NextCure compare to Elutia?

Does the media refer more to ELUT or NXTC?

Which has stronger valuation & earnings, ELUT or NXTC?

Do insiders and institutionals believe in ELUT or NXTC?

Do analysts recommend ELUT or NXTC?

Which has more risk and volatility, ELUT or NXTC?

Is ELUT or NXTC more profitable?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

NXTC vs. The Competition

NextCure Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools